IP Library Granted Patent US 9,545,419
Granted Patent B1
US 9,545,419 · App. 14/950,030 · Granted Jan 17, 2017

Method and compositions for treating chronic inflammatory disorders

Inventor: Joel E Bernstein (Highland Park, IL)
Assignee: ELORAC INC
A61K31/7084A61K9/0019A61K9/0053A61K9/48A61K31/12A61K31/202A61K31/352A61K31/353A61K31/455
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,545,419
App. No.
14/950,030
Granted
Jan 17, 2017
Kind
B1
Abstract

A method and composition for treating chronic inflammatory disorders comprising a pharmaceutically acceptable carrier suitable for oral administration or injection and containing a therapeutic amount of a complex of dietary supplement ingredients comprising nicotinamide, quercetin, curcumin, EPA, DHA, hesperetin and glychrrhizin.

Claims (24)

1. A method of treating chronic inflammatory disorders in humans in need of such treatment comprising administering an immune-modulating dietary supplement complex containing a therapeutically effective amount of nicotinamide, quercetin, curcumin, EPA, DHA, hesperetin and glycyrrhizin.

2. The method of claim 1 , wherein the dietary supplement ingredients are present in percentage ranges shown in the table below

% By Weight in

Ingredient

Oral Dosage Form

Nicotinamide

20-40

Quercetin

10-15

Curcumin

10-20

EPA

12-26

DHA

 4-12

Hesperetin

0.4-1  

Glycyrrhizin

 1-4.

3. The method of claim 1 , wherein the daily dosage of the dietary supplement complex is from about 400 mg to about 4000 mg.

4. The method of claim 1 , wherein the daily dosage of the dietary supplement complex of about 400 mg to about 4000 mg is administered once daily or in divided doses administered 2 to 4 times per day.

5. The method of claim 1 , wherein the ratio of EPA to DHA (EPA/DHA) must be ≧2.5 and ≦3.2 and the ratio of nicotinamide to the combination of quercetin and curcumin must be ≧0.80 and ≦1.50.

6. The method of claim 1 , wherein the pharmaceutically acceptable carrier includes tablets, capsules, caplets, and solutions or suspensions, suitable for oral ingestion.

7. The method of claim 1 , wherein the pharmaceutically acceptable carrier includes sterile solutions or suspensions suitable for intravenous or subcutaneous injection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2023
From: ELORAC, INC.
To: ELORAC CREDITORS TRUST
Reel/Frame 065074/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2016
From: BERNSTEIN, JOEL E., M.D.
To: ELORAC INC.
Reel/Frame 040094/0916 →